ࡱ> => l \pThe Free Software Foundation B=PF0*8X@"1 Helvetica1Courier1 Courier New1 Courier New1 Helvetica$#,##0_);($#,##0)$#,##0_);[Red]($#,##0)$#,##0.00_);($#,##0.00)$#,##0.00_);[Red]($#,##0.00)-**_($* #,##0_);_($* (#,##0);_($* "-"_);_(@_)*)'_(* #,##0_);_(* (#,##0);_(* "-"_);_(@_)5,2_($* #,##0.00_);_($* (#,##0.00);_($* "-"??_);_(@_)2+/_(* #,##0.00_);_(* (#,##0.00);_(* "-"??_);_(@_)2$#,##0.00;[Red]$#,##0.003$#,##0.00;[Red]($#,##0.00)4$#,##0;[Red]($#,##00)50.00%;[Red](0.00%)6 0%;[Red](0%)7#,##0.00;[Red](#,##0.00)8#,##0;[Red](#,##0)                + ) , *   Ј ~~ ؈ ~~#؈ ~~ ؈ ~~<#܈ ~~8#܈ ~~7#܈ ~~4#܈ ~~83ffff̙̙3f3fff3f3f33333f33&FUTURE NET REVENUES AND PRESENT%IITEM 6 SELECTED FINANCIAL DATA&Summary Compensation%K1ITEM 11 EXECUTIVE COMPENSATION&<REPORT OF INDEPENDENT CERTIFIEDnNO TITLE l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/?? ITEM 6 SELECTED FINANCIAL DATASummary Compensation ITEM 11 EXECUTIVE COMPENSATION!REPORT OF INDEPENDENT CERTIFIED NO TITLEU } y } } a/} =}  Y} i} U      TherapeuticsMD, Inc. 10-K 04/01/1996.&FUTURE NET REVENUES AND PRESENT VALUES         Proved Devel  Developed Proved U  Undeveloped Tot Total ________ _____________________/ '_______________________________________; 3___________________________________________________R J__________________________________________________________________________` X________________________________________________________________________________________s k___________________________________________________________________________________________________________   Present  Present  PresentFutureValue ofFutureValue ofFutureValue of As of Net Future Net Net Future Net Net Future Net 12/31RevenueRevenueRevenueRevenueRevenueRevenue~ &~ *l.~ μ~ jd~ + ~ ?~ (~ *~ Vy3~ A ~ J~ A ~ B~ ރ,~ .~ 4~  ~ ~ b ~ C~ ~,_____________________________/'_______________________________________;3___________________________________________________RJ__________________________________________________________________________`X________________________________________________________________________________________sk___________________________________________________________________________________________________________$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/8 |pdXL@?A\=PF0*8X> @ l  *"O&  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??!FUTURE NET REVENUES AND PRESENTSummary Compensation ITEM 11 EXECUTIVE COMPENSATION!REPORT OF INDEPENDENT CERTIFIED NO TITLEU } m)} y<} Q} $f} x}  *     TherapeuticsMD, Inc. 10-K 04/01/1996'ITEM 6. SELECTED FINANCIAL DATA   * "__________________________________: 2__________________________________________________L D____________________________________________________________________] U_____________________________________________________________________________________l d____________________________________________________________________________________________________v n______________________________________________________________________________________________________________* " F Fiscal Year Ended  December 31: ~ ~ "~ &~ *~ .*"__________________________________:2__________________________________________________LD____________________________________________________________________]U_____________________________________________________________________________________ld____________________________________________________________________________________________________vn______________________________________________________________________________________________________________REVENUES Operations Oil and Gas~ 2 ~ . ~ zG ~  ~   Other Revenues~ ~ Fm~ v~ _~ Expenses~ b ~ ھ ~ / ~ 2 ~ ~  Net Income~ 6L~ l~ N~ ~ ^)! Net Income Per Common Share (1)Q?{Gz?{Gz?Q?Q?Working capital~ q~ ~ ڒ~ ~ fLong-term debt Total assets~ BO~ ~ ~ C~ D lwk_SG81|uaJ{!<0aUI !"#$%&'()  Stockholders'! equity~ !*y~ !~ !z~ !~ !>"Dividends per share "NONE "NONE "NONE "NON "NONE # NONE*$"__________________________________:$2__________________________________________________I$A_________________________________________________________________%&$'____________________________1()Created by Morningstar Document Research.0)(http://documentresearch.morningstar.com/ VJ>=PF0*8X> @))(('' l  0  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??!FUTURE NET REVENUES AND PRESENT ITEM 6 SELECTED FINANCIAL DATA ITEM 11 EXECUTIVE COMPENSATION!REPORT OF INDEPENDENT CERTIFIED NO TITLEU } } 1} 0G} d}       TherapeuticsMD, Inc. 10-K 04/01/1996Summary Compensation  ________________1 )_________________________________________C ;___________________________________________________________\ T____________________________________________________________________________________t l____________________________________________________________________________________________________________   Summary Compensati Compensation Table  ~ ." Compensation of C.E.O. (1) Salary Bonus Other Stock Options Total All Compensations 48,000 per~ ~ ~ ~  annum________________1)_________________________________________C;___________________________________________________________\T____________________________________________________________________________________tl____________________________________________________________________________________________________________$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/6vj^RB61a=PF0*8X> @ l  <  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??!FUTURE NET REVENUES AND PRESENT ITEM 6 SELECTED FINANCIAL DATASummary Compensation!REPORT OF INDEPENDENT CERTIFIED NO TITLEU } } y<}  @ l  $EpMU#^Ggm  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??!FUTURE NET REVENUES AND PRESENT ITEM 6 SELECTED FINANCIAL DATASummary Compensation ITEM 11 EXECUTIVE COMPENSATION NO TITLEU } ? ~ F"~ ֩"!+"# Less accumulated depletion and # depreciation~ #f~ #$%~ %~ %t&-'% Furniture, fixtures and equipment~ 'F~ ',($ Less accumulated depreciation~ ("~ ()*~ *~ *+0,( Net property and equipment~ ,~ ,t- .Coal investment (Note 2)~ .~ ./0~ 0C~ 0R1J LIABILITIES AND STOCKHOLDERS' EQUITY23~ 3*~ 3.4Current liabilities:5 Accounts payable~ 5ڪ~ 566 Accrued liabilities~ 6f~ 6:9!7 Note payable (Note 2)~ 7~ 7B 8+9# Total current liabilities~ 9>~ 9:&;Commitments (Notes 2, 4 and 9)<.=&Stockholders' equity (Notes 5 and 10):)>! Common stock, .10 par value; -?% 20,000,000 shares authorized, DlbV."}UIy#TzH@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_$@ 579,143 shares issued~ @~ @*A" Capital in excess of par value~ A~7~ A~7B Accumulated deficit~ B~ B2CD~ D:~ D)E! Less treasury stock at cost, (F 52,788 shares (1994) and #G 62,628 shares (1995)~ Gj~ GH,I$ Total stockholders' equity~ I~ I>JK~ KC~ K~ L&~ L*~ L.MRevenue:%N Oil and gas sales (Note 8)~ N ~ N .O& Gain (loss) on disposal of oil and P gas properties~ P"~ PRQ Other income~ Q_~ QNCRS Total revenue~ SH ~ Sډ TUCosts and expenses:"V Lease operating expense~ V>,~ Vd&W General and administrative X (Note 3)~ X^~ X*'Y Rent expense - related partyZ (Note 4)~ Z~ Z%[ Depreciation and depletion~ [~ [\ Interest~ \~ \G]*^" Total costs and expenses~ ^2 ~ ^~ _D'lr3'cW T"cW8j3`abcdefghijklmnopqrstuvwxyz{|}~`Net income (Note 6)~ `~ `^a%bNet income per share (Note 7)bQ?bQ?c cCapitc Capital inKdC Common Stockd excess ofdTreasuryGe? Sharese par value estockf"gBalance, December 31, 1992~ g~7~ gh%i Purchase of 100 shares of j Treasury stock~ j~ j^kl)m! Net income for the year ended  n December 31, 1993~ nn-42,579o"pBalance, December 31, 1993~ p~7~ pjq)r! Net income for the year ended s"tBalance, December 31, 1994~ t~7~ tju'v Purchase of 9,840 shares of &w treasury stock (Note 5)~ w~ wBfx#y Net income for the year &z ended December 31, 1995~ z~ z^~ {&~ {.|-}%Cash flows from operating activities:~ Net income~31,511/' Adjustments to reconcile net income Dll9PDxKs1%;' to net cash provided by $ operating activities:,$ Depreciation and depletion30,245-% Loss (gain) on disposal of  properties(5,289)3+ Loss (gain) on marketable equity  securities (60)" Bad debt expense -3+ Change in assets and liabilities:4, Decrease (increase) in accounts# receivable 4,0225- Increase (decrease) in accounts   payable (105)4, Increase (decrease) in accrued $ liabilities 3,125,$ Total adjustments31,938;3 Net cash provided by operating activities 59,76463,449-%Cash flows from investing activities: Note receivable 700,$ Proceeds from sale and leases of  property11,285,$ Purchase of oil and gas interests(10,557)<4 Purchase of marketable equity securities (16,660) -,$ Proceeds from sale of marketable   equity securities 8,810& Purchase of coal investment (100,000)-% Distributions from coal investment 4,7010( Net cash used in investing activities(85,061)Dlk:g0R6*o+y:-%Cash flows from financing activities:% Purchase of treasury stock(9,840)% Proceeds from note payable50,000*" Net cash provided by (used in) # financing activities40,160#Increase (decrease) in cash18,548!Cash at beginning of year19,385Cash at end of year37,9334,Supplemental disclosure of cash information:ME During the year ended December 31, 1995, the Company paid cash for+# interest in the amount of 4,138.PH See accompanying notes.C; C; F-7$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/:oL@QEsD8VJ>=PF0*8X> @ l  6tx  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??!FUTURE NET REVENUES AND PRESENT ITEM 6 SELECTED FINANCIAL DATASummary Compensation ITEM 11 EXECUTIVE COMPENSATION!REPORT OF INDEPENDENT CERTIFIEDU } $ 6     TherapeuticsMD, Inc. 10-K 04/01/1996NO TITLE      D6lvj^R:." znb !"#$%&'()*+,-./012345 !"#$%&'()*+,-./0012$3____________________________14)Created by Morningstar Document Research.05(http://documentresearch.morningstar.com/09|pdXL@(=PF0*8X> @554433 Root Entry FBook  x  !"#$%&'()*+,-./0123456789:;<